Man-made superantigens: Tumor-selective agents for T-cell-based therapy

Advanced Drug Delivery Reviews

Volumn 31, Issue 1-2, 1998, Pages 131-142

  Brodin, Thomas N ^a   Persson, Robert ^a   Soegaard, Morten ^a   Ohlsson, Lennart ^a   D'Argy, Roland ^a   Olsson, Jesper ^a   Molander, Anna ^a   Antonsson, Per ^a   Gunnarsson, Per Olov ^a   Kalland, Terje ^a   Dohlsten, Mikael ^a  

^a Pharmacia & Upjohn AB   (Sweden)

Author keywords

Monoclonal antibodies; Protein pharmaceuticals; Staphylococcal enterotoxin A (SEA); Superantigen; T cell activation; Tumor immunotherapy

Indexed keywords

ANTIGENS; BACTERIA; MOLECULAR STRUCTURE; MONOCLONAL ANTIBODIES; MUTAGENESIS; ONCOLOGY; PHARMACOKINETICS; TOXICITY; VIRUSES;

SUPERANTIGENS;

CONTROLLED DRUG DELIVERY;

HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; GENE FUSION; GENETIC ENGINEERING; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032489810     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00097-5     Document Type: Review

References (39)

1. Urban J.L., Schreiber H. Tumor antigens. Annu. Rev. Immunol. 10:1992;617-644.
2. Marincola F.M., Ettinghausen S., Cohen P.A., Cheshire L.B., Restifo N.P., Mule J.J., Rosenberg S.A. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J. Immunol. 152:1994;3500-3513.
3. Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J., Yannelli J.R., Rosenberg S.A. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88:1996;100-108.
4. Riethmuller G., Schneider Gadicke E., Johnson J.P. Monoclonal antibodies in cancer therapy. Curr. Opin. Immunol. 5:1993;732-739.
5. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408.
6. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 248:1990;705-711.
7. Kotzin B.L., Leung D.Y., Kappler J., Marrack P. Superantigens and their potential role in human disease. Adv. Immunol. 54:1993;99-166.
8. Y.M. Leung, B.T. Hubert, P.M. Schlievert, Historical perspective of superantigens and their biological activities, in: Y.M. Leung, B.T. Hubert, P.M. Schlievert (Eds.), Superantigens. Molecular Biology, Immunology, and relevance to Human Disease, Marcel Dekker, 1997, pp. 1-13.
9. Scherer M.T., Ignatowicz L., Winslow G.M., Kappler J.W., Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. Annu. Rev. Cell Biol. 9:1993;101-128.
10. Kalland T., Hedlund G., Dohlsten M., Lando P.A. Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. Curr. Top. Microbiol. Immunol. 174:1991;81-92.
11. Dohlsten M., Hedlund G., Akerblom E., Lando P.A., Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc. Natl. Acad. Sci. USA. 88:1991;9287-9291.
12. Dohlsten M., Abrahmsen L., Bjork P., Lando P.A., Hedlund G., Forsberg G., Brodin T., Gascoigne N.R., Forberg C., Lind P., Kalland T. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc. Natl. Acad. Sci. USA. 91:1994;8945-8949.
13. Dohlsten M., Hansson J., Ohlsson L., Litton M., Kalland T. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;9791-9795.
14. Antonsson P., Hansson J., Kalland T., Lando P.A., Ohlsson L., Schad E., Svensson A., Dohlsten M. Genetically engineered superantigens in experimental tumor therapy. Springer Semin. Immunopathol. 17:1996;397-410.
15. Soegaard M., Hansson J., Litton M.J., Ohlsson L., Rosendahl A., Lando P., Antonsson P., Kalland T., Dohlsten M. Antibody-targeted superantigens in cancer immunotherapy. Immunotechnology. 2:1996;151-162.
16. L.A. Svensson, E.M. Schad, M. Sundstrom, P. Antonsson, T. Kalland, M. Dohlsten, Staphylococcal enterotoxins A, D and E: structure and function, including mechanism of T-cell superantigenicity, in: B.T. Hubert, Y.M. Leung, P.M. Schlievert (Eds.), Superantigens. Molecular Biology, Immunology and relevance to Human Disease, Marcel Dekker, 1997, pp. 199-229.
17. Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G., Chi Y.I., Stauffacher C., Strominger J.L., Wiley D.C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 368:1994;711-718.
18. Mehindate K., Thibodeau J., Dohlsten M., Kalland T., Sekaly R.P., Mourad W. Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J. Exp. Med. 182:1995;1573-1577.
19. Schad E.M., Zaitseva I., Zaitsev V.N., Dohlsten M., Kalland T., Schlievert P.M., Ohlendorf D.H., Svensson L.A. Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J. 14:1995;3292-3301.
20. 2+ at 2.7 Å resolution. Implications for major histocompatibility complex class II binding. J. Biol. Chem. 271:1996;32212-32216.
21. Papageorgiou A.C., Acharya K.R., Shapiro R., Passalacqua E.F., Brehm R.D., Tranter H.S. Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site. Structure. 3:1995;769-779.
22. Ulrich R.G., Bavari S., Olson M.A. Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules. Nature Struct. Biol. 2:1995;554-560.
23. Abrahmsen L., Dohlsten M., Segren S., Bjork P., Jonsson E., Kalland T. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J. 14:1995;2978-2986.
24. Antonsson P., Wingren A.G., Hansson J., Kalland T., Varga M., Dohlsten M. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR. J. Immunol. 158:1997;4245-4251.
25. Miethke T., Wahl C., Regele D., Gaus H., Heeg K., Wagner H. Superantigen mediated shock: a cytokine release syndrome. Immunobiology. 189:1993;270-284.
26. Bette M., Schafer M.K., van Rooijen N., Weihe E., Fleischer B. Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen. J. Exp. Med. 178:1993;1531-1539.
27. R.L. Deresiewicz, Staphylococcal toxic shock syndrome, in: B.T. Hubert, Y.M. Leung, P.M. Schlievert (Eds.), Superantigens. Molecular Biology, Immunology, and relevance to Human Disease, Marcel Dekker, 1997, pp. 435-479.
28. Hedlund G., Dohlsten M., Lando P.A., Kalland T. Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells. Cell. Immunol. 129:1990;426-434.
29. Dohlsten M., Bjorklund M., Sundstedt A., Hedlund G., Samson D., Kalland T. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology. 79:1993;520-527.
30. Wallgren A., Festin R., Gidlof C., Dohlsten M., Kalland T., Totterman T.H. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T-cells. Blood. 82:1993;1230-1238.
31. Litton M.J., Dohlsten M., Hansson J., Rosendahl A., Ohlsson J., Kalland T., Andersson J., Andersson U. Tumor therapy with an antibody targeted superantigen generates a dichotomy between local and systemic immune responses. Am. J. Pathol. 150:1997;1607-1618.
32. Litton M.J., Dohlsten M., Lando P.A., Kalland T., Ohlsson L., Andersson J., Andersson U. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur. J. Immunol. 26:1996;1-9.
33. Rosendahl A., Hansson J., Sundstedt A., Kalland T., Dohlsten M. Immune response during tumor therapy with antibody-superantigen fusion proteins. Int. J. Cancer. 68:1996;109-113.
34. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J. Exp. Med. 169:1989;333-338.
35. Hansson J., Ohlsson L., Persson R., Andersson G., Ilbäck N., Litton M.J., Kalland T., Dohlsten M. Genetically engineered superantigens as tolerable antitumor agents. Proc. Natl. Acad. Sci. USA. 94:1997;2489-2494.
36. Dohlsten M., Lando P.A., Bjork P., Abrahmsen L., Ohlsson L., Lind P., Kalland T. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol. Immunother. 41:1995;162-168.
37. Bjork P., Jonsson U., Svedberg H., Larsson K., Lind P., Dillner J., Hedlund G., Dohlsten M., Kalland T. Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J. Biol. Chem. 268:1993;24232-24241.
38. S. Ullberg, B. Larsson, H. Tjälve, Autoradiography, in: H.J. Glenn (Ed.), Biological Applications of Radiotracers, CRC Press, 1982, pp. 55-108.
39. Ahr H.J., Steinke W. Imaging plate: validation and first experience with quantitative studies in whole body autoradiography during drug development. Xenobiotic Metab. Dispos. 9:1994;371-378.